
Sign up to save your podcasts
Or


In his weekly clinical update, Dr. Griffin discusses Merck's RSV preventative monoclonal antibody Clesrovimab before reviewing the recent statistics on SARS-CoV-2 infection, if previous SARS-COV-2 infections predict the outcome of subsequent infections, if using COVID rapid diagnostic tests is cost effective, if the protein based vaccine NVX-CoV2327 elicits a durable immune response, if combination treatment of vaccine and antiviral drugs effectively protect against hospitalization, where to find PEMGARDA, what do when healthcare workers succumb to SARS-CoV-2 infection, and how COVID-19 may alter the cognitive trajectories of older patients.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
By Vincent Racaniello4.7
209209 ratings
In his weekly clinical update, Dr. Griffin discusses Merck's RSV preventative monoclonal antibody Clesrovimab before reviewing the recent statistics on SARS-CoV-2 infection, if previous SARS-COV-2 infections predict the outcome of subsequent infections, if using COVID rapid diagnostic tests is cost effective, if the protein based vaccine NVX-CoV2327 elicits a durable immune response, if combination treatment of vaccine and antiviral drugs effectively protect against hospitalization, where to find PEMGARDA, what do when healthcare workers succumb to SARS-CoV-2 infection, and how COVID-19 may alter the cognitive trajectories of older patients.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]

43,987 Listeners

6,769 Listeners

4,040 Listeners

5,784 Listeners

3,531 Listeners

26,318 Listeners

2,061 Listeners

453 Listeners

521 Listeners

540 Listeners

12,164 Listeners

4,671 Listeners

277 Listeners

16,001 Listeners

88 Listeners